Approval · Notice of Compliance 12609 · 2011
PMS-MEMANTINE: Notice of Compliance 12609
Issued September 1, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12609
- Date
- September 1, 2011
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Removal of commitments as per the Letter of Undertaking dated August 28, 2009 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's Type.
- Therapeutic class
- N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-MEMANTINE | Not yet assigned | — |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 10 MG per TAB